Stoke Therapeutics Inc (STOK) Stock Price, Quote & News

Company Profile

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevun...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 430 8200

Website: www.stoketherapeutics.com

Address:

45 Wiggins Avenue, Bedford, United States

TheDizPlinTrader Feb. 24 at 1:42 PM

$STOK 🧬 1 Hour Levels Price: $36.31 Support: $34.90 Resistance: $38.10 👉 Tap follow to keep these 1-hour levels on your feed.

0 · Reply

WolferG Feb. 24 at 12:54 PM

$STOK looks like shit

0 · Reply

WolferG Feb. 24 at 12:47 PM

$STOK

0 · Reply

erevnon Feb. 24 at 12:42 PM

Wolfe Research initiates coverage on Stoke Therapeutics $STOK at Outperform rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

_PantherC Feb. 24 at 1:07 AM

*@SqueezeSharkie is operating on a whole different level, easily ahead of 90% of the traders on this platform. If you’re not paying attention yet, you’re missing out. Go give him a follow. It’s completely free and only takes a second 💎 $STOK $FLR $VALN $FRO 5

0 · Reply

ItsKrocodileTeeth Feb. 24 at 12:40 AM

Special thanks to @SqueezeSharkie for nailing that trade, He is worth Following for sure 💯 $ATEX $STOK $NCEW $SDA ~## Watch em

0 · Reply

_Meowzilla1 Feb. 23 at 4:20 PM

$CLPS $YDDL $AGIG $STOK [}{

0 · Reply

_Meowzilla1 Feb. 23 at 4:17 PM

$WORX $STOK $ZJK $LEGN /*/

0 · Reply

UgoGreg Feb. 21 at 4:20 PM

$STOK https://youtu.be/ygBN8MilTyc

0 · Reply

BillionerOfKing Feb. 18 at 6:02 PM

$STOK Current Stock Price: $31.32 Contracts to trade: $30.0 STOK Feb 20 2026 Call Entry: $0.25 Exit: $0.41 ROI: 63% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Feb 18, 2026, 4:01 PM EST - 6 days ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Feb 11, 2026, 7:30 AM EST - 13 days ago

Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)

Feb 4, 2026, 4:01 PM EST - 20 days ago

Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Jan 27, 2026, 2:05 PM EST - 4 weeks ago

Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA

Jan 15, 2026, 8:49 AM EST - 5 weeks ago

Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity

Jan 11, 2026, 2:00 PM EST - 6 weeks ago

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

BIIB

Jan 6, 2026, 4:01 PM EST - 7 weeks ago

Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 5, 2025, 9:00 AM EST - 2 months ago

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

BIIB

Dec 1, 2025, 7:30 AM EST - 3 months ago

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

BIIB

Nov 17, 2025, 7:30 AM EST - 3 months ago

Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments

BIIB

Nov 5, 2025, 4:01 PM EST - 3 months ago

Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 4, 2025, 4:01 PM EST - 4 months ago

Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Oct 30, 2025, 4:30 PM EDT - 4 months ago

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates

Oct 20, 2025, 7:30 AM EDT - 4 months ago

Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)

Oct 9, 2025, 4:30 PM EDT - 4 months ago

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

BIIB

Oct 6, 2025, 7:30 AM EDT - 5 months ago

Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer

Sep 2, 2025, 7:00 AM EDT - 6 months ago

Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome

BIIB

Aug 28, 2025, 4:30 PM EDT - 6 months ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in September 2025

Aug 25, 2025, 7:00 AM EDT - 6 months ago

Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

BIIB

Aug 12, 2025, 4:01 PM EDT - 7 months ago

Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 11, 2025, 7:00 AM EDT - 7 months ago

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

BIIB

Aug 7, 2025, 7:00 AM EDT - 7 months ago

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates

Aug 6, 2025, 4:30 PM EDT - 7 months ago

Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 16, 2025, 4:30 PM EDT - 7 months ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 10, 2025, 7:00 AM EDT - 8 months ago

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

BIIB

Jul 10, 2025, 7:00 AM EDT - 8 months ago

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

BIIB

Jun 15, 2025, 11:27 PM EDT - 9 months ago

Stoke Therapeutics: Impressive Pipeline And Big Backers

May 29, 2025, 7:30 AM EDT - 9 months ago

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

May 13, 2025, 7:00 AM EDT - 10 months ago

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 1, 2025, 4:30 PM EDT - 11 months ago

Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 18, 2025, 12:56 PM EDT - 1 year ago

Stoke Therapeutics Stock Slips as CEO Steps Down

Mar 18, 2025, 7:00 AM EDT - 1 year ago

Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 18, 2025, 6:58 AM EDT - 1 year ago

Stoke Therapeutics Announces CEO Transition

Feb 26, 2025, 4:30 PM EST - 1 year ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in March

Feb 18, 2025, 8:46 AM EST - 1 year ago

Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy

BIIB

$Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments$

Feb 18, 2025, 8:00 AM EST - 1 year ago

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

BIIB

Feb 16, 2025, 2:23 PM EST - 1 year ago

Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer

Jan 8, 2025, 4:30 PM EST - 1 year ago

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:00 AM EST - 1 year ago

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Jan 6, 2025, 4:30 PM EST - 1 year ago

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

Dec 6, 2024, 12:00 PM EST - 1 year ago

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Dec 5, 2024, 8:30 AM EST - 1 year ago

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

BIIB PRAX WGS

Dec 4, 2024, 7:00 AM EST - 1 year ago

Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome

Dec 2, 2024, 8:00 AM EST - 1 year ago

Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting

Nov 5, 2024, 7:00 AM EST - 1 year ago

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Sep 10, 2024, 7:00 AM EDT - 1 year ago

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome

Sep 7, 2024, 4:03 AM EDT - 1 year ago

Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

TheDizPlinTrader Feb. 24 at 1:42 PM

$STOK 🧬 1 Hour Levels Price: $36.31 Support: $34.90 Resistance: $38.10 👉 Tap follow to keep these 1-hour levels on your feed.

0 · Reply

WolferG Feb. 24 at 12:54 PM

$STOK looks like shit

0 · Reply

WolferG Feb. 24 at 12:47 PM

$STOK

0 · Reply

erevnon Feb. 24 at 12:42 PM

Wolfe Research initiates coverage on Stoke Therapeutics $STOK at Outperform rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

_PantherC Feb. 24 at 1:07 AM

0 · Reply

ItsKrocodileTeeth Feb. 24 at 12:40 AM

Special thanks to @SqueezeSharkie for nailing that trade, He is worth Following for sure 💯 $ATEX $STOK $NCEW $SDA ~## Watch em

0 · Reply

_Meowzilla1 Feb. 23 at 4:20 PM

$CLPS $YDDL $AGIG $STOK [}{

0 · Reply

_Meowzilla1 Feb. 23 at 4:17 PM

$WORX $STOK $ZJK $LEGN /*/

0 · Reply

UgoGreg Feb. 21 at 4:20 PM

$STOK https://youtu.be/ygBN8MilTyc

0 · Reply

BillionerOfKing Feb. 18 at 6:02 PM

0 · Reply

ValuationExpert Feb. 18 at 4:38 PM

$STOK Stoke Therapeutics focuses on RNA-based therapies. Clinical data drives valuation. Cash runway supports development.

0 · Reply

ClinicalTrialsDaily Feb. 12 at 7:13 PM

$STOK Clinical pivot point: STK-002 OSPREY trial vs SOC $SANN (Idebenone). Differentiation: 1. SOC = Metabolic bandaid (Oral) 2. STK-002 = Genetic fix (IVT ASO) Key Risk: Ocular inflammation (Endophthalmitis). ADOA is slowly progressive, so safety bar is higher than LHON. Structural RNFL endpoints > VA for early signal. Watch Q4 2026 data. $PYC Read more: www.clinicaltrialsdaily.com/stk-002-adoa-disease-modifying-potential/

0 · Reply

TheTradeXchange Feb. 11 at 12:30 PM

$STOK Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)

0 · Reply

BillionerOfKing Feb. 9 at 12:41 PM

$STOK Current Stock Price: $32.37 Contracts to trade: $30.0 STOK Feb 20 2026 Call Entry: $3.12 Exit: $4.31 ROI: 38% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

notreload_ai Feb. 5 at 1:57 PM

Guggenheim initiates coverage on $STOK , highlighting Zorevunersen’s potential as a disease-modifying treatment for Dravet syndrome and projecting $2.5B peak sales. https://notreload.xyz/guggenheim-starts-coverage-on-stoke-therapeutics-with-buy-rating-and-60-target/

0 · Reply

Quantumup Feb. 5 at 12:25 PM

Guggenheim🏁 $STOK Buy/$60 $BIIB $PRAX DRUG UCBJY UCBJF JAZZ Guggenheim said in its initiation report: Our investment thesis on STOK centers around our positive view of its lead asset, zorevunersen, a first-in-class antisense oligonucleotide (ASO) designed to restore SCN1A haploinsufficiency, the root cause of Dravet syndrome (DS), by upregulating NaV1.1 expression. Guggenheim went on to say: https://x.com/Quantumup1/status/2019385972002111518?s=20

0 · Reply

DeltaDivergence Feb. 4 at 1:32 PM

$STOK is a beverage company with a portfolio of functional and better-for-you brands; it faces intense competition in the crowded non-alcoholic drink space and requires continuous marketing investment.

0 · Reply

SuperGreenToday Jan. 22 at 4:35 PM

$STOK Share Price: $29.99 Contract Selected: Aug 21, 2026 $30 Calls Buy Zone: $4.67 – $5.78 Target Zone: $8.50 – $10.38 Potential Upside: 72% ROI Time to Expiration: 210 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

ClinicalTrialsDaily Jan. 20 at 6:58 PM

$STOK Consolidated Analysis: Zorevunersen is a transformative asset with 1.3B peak sales potential. It outperforms UCB Fintepla in seizure data (~85% vs ~70%) but faces higher delivery hurdles (Intrathecal vs Oral). The investment thesis relies on Ph3 confirming cognitive benefits to justify the procedure. M&A potential is high if it becomes the 'Spinraza of Epilepsy' before gene therapies arrive. #Biotech #Pharma #Investing Read more: www.clinicaltrialsdaily.com/zorevunersen-stk-001-dravet-syndrome-efficacy/

0 · Reply

garygb Jan. 12 at 3:27 PM

$STOK It's the wild wild west out there. This top rated analyst favorite is down 17% today because........

0 · Reply

AStrokeOfLuck Jan. 12 at 3:12 PM

$STOK

0 · Reply

OpenOutcrier Jan. 12 at 1:58 PM

$STOK (-17.2% pre) Stoke Therapeutics Accelerates Phase 3 Dravet Study Timeline https://ooc.bz/l/89387

0 · Reply

Market Cap	2.07B
Revenue (ttm)	36.56M
Net Income (ttm)	-88.98M
EPS (ttm)	N/A
PE Ratio	51.18
Forward PE	N/A
Profit Margin	-243.38%
Debt to Equity Ratio	0.00

Volume	851,000
Avg Vol	751,080
Day's Range	N/A - N/A
Shares Out	57.12M
Stochastic %K	69%
Beta	1.10
Analysts	Strong Sell
Price Target	$41.89